• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
Menu
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Opiant Pharmaceuticals gets additional funding for intranasal nalmefene

Opiant Pharmaceuticals has received an additional $3 million from a 3-year grant awarded in 2018 by the National Institutes of Health’s (“NIH”) National Institute on Drug Abuse (“NIDA”) to support development of OPNT003 intranasal nalmefene for the treatment of opioid overdose. The company previously received $2.6 million from the grant, which is worth up to a total of $7.4 million.

According to Opiant, the company intends to submit an NDA for OPNT003 in 2020, using the 505(b)(2) development pathway. Opiant has already announced that Consort Medical subsidiaries Aesica and Bespak will manufacture the product if the NDA is approved.

Opiant CEO Roger Crystal said, “The award of this second tranche validates the progress we have achieved to date with OPNT003. We will use these funds in 2019 to advance the program, including conducting a pivotal pharmacokinetic study. The development of stronger, longer-acting opioid overdose reversal products that potentially better address the next wave of potent synthetic opioids, like fentanyl, remains a critical area of focus for the NIH, and we are appreciative of their continued support.”

Read the Opiant Pharmaceuticals press release.

Share

published on April 2, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • May 13-May 14: Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course 24, online
  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews